Prabhdeep Kaur, Kamaraj Pattabi, Amirthammal Gunasekaran, Vettrichelvan Venkatasamy, Azhagendran Sivalingam, Sabarinathan Ramasamy, Sailaja Bitragunta, Tapas Chakma, Sampada D Bangar, Meenakshi Sharma, Abhishek Kunwar, Kiran Durgad, Anupam K Pathni, Sandeep S Gill, Padmaja Jogewar, Madhavi Mallela, Ashish Saxsena, Bipin Gopal, Bidisha Das, Vishwajit Bharadwaj, Pooja Gaigaware, Sreedhar Chintala, Chakshu Joshi, Rupali Bharadwaj, Suyesh Shrivastava, Pankaj Uike, Yannick P Puthussery, Gopinath T Sambandam, R S Dhaliwal, Balram Bhargava
{"title":"Population-based surveillance for hypertension awareness, treatment, and control in nine districts - India Hypertension Control Initiative, 2018-19.","authors":"Prabhdeep Kaur, Kamaraj Pattabi, Amirthammal Gunasekaran, Vettrichelvan Venkatasamy, Azhagendran Sivalingam, Sabarinathan Ramasamy, Sailaja Bitragunta, Tapas Chakma, Sampada D Bangar, Meenakshi Sharma, Abhishek Kunwar, Kiran Durgad, Anupam K Pathni, Sandeep S Gill, Padmaja Jogewar, Madhavi Mallela, Ashish Saxsena, Bipin Gopal, Bidisha Das, Vishwajit Bharadwaj, Pooja Gaigaware, Sreedhar Chintala, Chakshu Joshi, Rupali Bharadwaj, Suyesh Shrivastava, Pankaj Uike, Yannick P Puthussery, Gopinath T Sambandam, R S Dhaliwal, Balram Bhargava","doi":"10.1038/s41371-025-01005-9","DOIUrl":null,"url":null,"abstract":"<p><p>Hypertension control is the crucial indicator for cardiovascular disease programs. We conducted a baseline cross-sectional survey to estimate hypertension awareness, treatment, and control in the selected districts in 2018-19, where the India Hypertension Control Initiative is being implemented. We conducted cross-sectional surveys in nine project districts for 18-69 years age group. The sample size was 624 per district. The study population was individuals with raised BP/diagnosed HT. We estimated the proportion and 95% confidence intervals (CI) for each district's awareness, treatment, and control. We computed unadjusted and adjusted prevalence ratios (APR) with 95% CI for factors associated with BP control. Hypertension was defined as systolic blood pressure (SBP) > = 140 or diastolic blood pressure (DBP) > = 90 mmHg or treatment in the previous two weeks. Control was defined as SBP < 140 and DBP < 90 mmHg. Among 7047 who had hypertension, 52.4% were aware, 40.8% were on treatment, and 14.5% had BP control. BP control was below 5% in two districts, 5-15% in three districts, and more than 15% in four districts. Among hypertensives aware of the diagnosis, the factors (APR with 95% CI) associated with control were lack of alcohol consumption [1.28 (1.09-1.52)], recent visit to government [1.98 (1.57-2.50)] or private facility [1.99 (1.61-2.46)] and treatment with single drug [2.40 (1.98-2.90)] or multiple drugs [2.84 (2.27-3.55)]. The simple, rapid population-based surveys can document awareness, treatment, and control changes. Improving access to treatment for hypertension through the public or private sector should be a high priority for India.</p>","PeriodicalId":16070,"journal":{"name":"Journal of Human Hypertension","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Human Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41371-025-01005-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
Abstract
Hypertension control is the crucial indicator for cardiovascular disease programs. We conducted a baseline cross-sectional survey to estimate hypertension awareness, treatment, and control in the selected districts in 2018-19, where the India Hypertension Control Initiative is being implemented. We conducted cross-sectional surveys in nine project districts for 18-69 years age group. The sample size was 624 per district. The study population was individuals with raised BP/diagnosed HT. We estimated the proportion and 95% confidence intervals (CI) for each district's awareness, treatment, and control. We computed unadjusted and adjusted prevalence ratios (APR) with 95% CI for factors associated with BP control. Hypertension was defined as systolic blood pressure (SBP) > = 140 or diastolic blood pressure (DBP) > = 90 mmHg or treatment in the previous two weeks. Control was defined as SBP < 140 and DBP < 90 mmHg. Among 7047 who had hypertension, 52.4% were aware, 40.8% were on treatment, and 14.5% had BP control. BP control was below 5% in two districts, 5-15% in three districts, and more than 15% in four districts. Among hypertensives aware of the diagnosis, the factors (APR with 95% CI) associated with control were lack of alcohol consumption [1.28 (1.09-1.52)], recent visit to government [1.98 (1.57-2.50)] or private facility [1.99 (1.61-2.46)] and treatment with single drug [2.40 (1.98-2.90)] or multiple drugs [2.84 (2.27-3.55)]. The simple, rapid population-based surveys can document awareness, treatment, and control changes. Improving access to treatment for hypertension through the public or private sector should be a high priority for India.
期刊介绍:
Journal of Human Hypertension is published monthly and is of interest to health care professionals who deal with hypertension (specialists, internists, primary care physicians) and public health workers. We believe that our patients benefit from robust scientific data that are based on well conducted clinical trials. We also believe that basic sciences are the foundations on which we build our knowledge of clinical conditions and their management. Towards this end, although we are primarily a clinical based journal, we also welcome suitable basic sciences studies that promote our understanding of human hypertension.
The journal aims to perform the dual role of increasing knowledge in the field of high blood pressure as well as improving the standard of care of patients. The editors will consider for publication all suitable papers dealing directly or indirectly with clinical aspects of hypertension, including but not limited to epidemiology, pathophysiology, therapeutics and basic sciences involving human subjects or tissues. We also consider papers from all specialties such as ophthalmology, cardiology, nephrology, obstetrics and stroke medicine that deal with the various aspects of hypertension and its complications.